SCHEMBL1907803

SCHEMBL1907803

COc1ccc(N)cc1-c1c(C)noc1C.COc1ccc(N)cc1-c1c(C)noc1C

nearest known ligand 0.48

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 14/20 0.48
BRD2 P25440 8/20 0.48
BRD3 Q15059 7/20 0.48
NR3C1 P04150 1/20 0.45
FFAR1 O14842 1/20 0.43
ATAD2 Q6PL18 1/20 0.43
ERN1 O75460 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1906132 1.00 BRD4 (0.48) BRD4BRD2BRD3NR3C1FFAR1
SCHEMBL16896898 0.88 BRD4 (0.48) BRD4BRD2BRD3NR3C1ATAD2
SCHEMBL17467705 0.87 MAP4K4 (0.40) BRD4BRD2BRD3NR3C1ATAD2
SCHEMBL15314278 0.84 BRD4 (0.50) BRD4BRD2BRD3NR3C1FFAR1
SCHEMBL29619075 0.81 BRD4 (0.45) BRD4BRD2BRD3FFAR1ATAD2
SCHEMBL11980660 0.81 BRD4 (0.47) BRD4BRD2BRD3ATAD2
SCHEMBL1907809 0.81 BRD4 (0.48) BRD4BRD2BRD3NR3C1FFAR1
SCHEMBL16619524 0.80 ATAD2 (0.46) BRD4BRD2BRD3FFAR1ATAD2
SCHEMBL13732133 0.79 BRD4 (0.47) BRD4BRD2BRD3NR3C1FFAR1
SCHEMBL19422785 0.79 BRD4 (0.50) BRD4BRD2BRD3NR3C1ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2699573-B1 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES GLAXOSMITHKLINE LLC (US) 2017-05-31 EP disclosed
US-8846709-B2 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives GLAXOSMITHKLINE LLC (US) 2014-09-30 US disclosed
EP-2699573-A2 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES Glaxosmithkline LLC (US) 2014-02-26 EP disclosed
US-20140045834-A1 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives GLAXOSMITHKLINE LLC (US) 2014-02-13 US disclosed
EP-2496576-B1 IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-12-18 EP disclosed
US-8557984-B2 Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 US disclosed
WO-2012143416-A2 NOVEL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2012-10-26 WO disclosed
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors GLAXOSMITHKLINE LLC 2012-09-13 US disclosed
EP-2496576-A1 IMIDAZO [4, 5-C]QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS GlaxoSmithKline LLC (US) 2012-09-12 EP disclosed
WO-2011054846-A1 IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045834-A1 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT2B7, UGT1A7 BRD4 5/4885BRD2 475/4885BRD3 96/4885
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors BRD4, BRD3, BRPF3 BRD4 1/4885BRD2 5/4885BRD3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.